Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 382
Filtrar
1.
Anticancer Res ; 41(2): 557-565, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33517261

RESUMO

Long non-coding RNAs (lncRNAs) are over 200 nucleotides long recently discovered RNA molecules that are not involved in the translation process. Accumulating evidence shows that H19 lncRNA is an important regulator of gene expression and its altered expression contributes to carcinogenesis. The aim of this review was to reveal current knowledge about H19 lncRNA and its impact on tumours of the endocrine system. We present findings about H19 altered regulation and its association with tumorigenesis, cancer progression and differentiation, and its potential use in diagnostics, prognostics and therapy. The mechanism and molecular pathways involved in these processes are discussed.


Assuntos
Transformação Celular Neoplásica/metabolismo , Doenças do Sistema Endócrino/metabolismo , Sistema Endócrino/metabolismo , Neoplasias/metabolismo , RNA Longo não Codificante/metabolismo , Animais , Diferenciação Celular , Proliferação de Células , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/patologia , Sistema Endócrino/patologia , Doenças do Sistema Endócrino/genética , Doenças do Sistema Endócrino/patologia , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias/genética , Neoplasias/patologia , RNA Longo não Codificante/genética , Transdução de Sinais
3.
Head Neck ; 42(6): 1325-1328, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32437031

RESUMO

BACKGROUND: In the face of the COVID-19 pandemic, cancer care has had to adapt rapidly given the Centers for Disease Control and Prevention and the American College of Surgeons (ACS) issuing recommendations to postpone nonurgent surgeries. METHODS: An institutional multidisciplinary group of Head and Neck Surgical Oncology, Surgical Endocrinology, and Medical Endocrinology devised Surgical Triaging Guidelines for Endocrine Surgery during COVID-19, aligned with phases of care published by the ACS. RESULTS: Phases of care with examples of corresponding endocrine cases are outlined. Most cases can be safely postponed with active surveillance, including most differentiated and medullary thyroid cancers. During the most acute phase, all endocrine surgeries are deferred, except thyroid tumors requiring acute airway management. CONCLUSIONS: These guidelines provide context for endocrine surgery within the spectrum of surgical oncology, with the goal of optimal individualized multidisciplinary patient care and the expectation of significant resource diversion to care for patients with COVID-19.


Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Doenças do Sistema Endócrino/cirurgia , Seleção de Pacientes , Pneumonia Viral/epidemiologia , Triagem , Algoritmos , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/transmissão , Doenças do Sistema Endócrino/patologia , Humanos , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Pneumonia Viral/transmissão , Guias de Prática Clínica como Assunto
4.
Eur J Endocrinol ; 182(6): R101, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32234976

RESUMO

Sexual function is an important component of either general health and quality of life in both genders. Many studies have focused on the different risk factors for sexual dysfunctions, proving an association with several medical conditions. Endocrine disorders have been often mentioned in the pathogenesis of female and male sexual dysfunctions; however, particularly in women, sexual function is rarely addressed during clinical, in general, and endocrinological, in particular, consultations. As a thorough diagnosis is required in order to provide an adequately tailored treatment, knowing how each endocrine dysfunction can impair sexual health is of the utmost importance, considering the high prevalence of conditions such as disorders of pituitary, thyroid, adrenal, gonads, as well as metabolic disorders. We performed a thorough review of existing literature on the different mechanisms involved in the pathogenesis of female sexual dysfunctions secondary to endocrine disorders in order to provide an up-to-date reference.


Assuntos
Disfunções Sexuais Fisiológicas/patologia , Disfunções Sexuais Psicogênicas/patologia , Gerenciamento Clínico , Doenças do Sistema Endócrino/complicações , Doenças do Sistema Endócrino/patologia , Feminino , Humanos , Disfunções Sexuais Fisiológicas/etiologia , Disfunções Sexuais Psicogênicas/etiologia
5.
Eur J Med Genet ; 63(1): 103614, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30654153

RESUMO

In everyday practice, a pediatric endocrinologist will face a variety of different endocrine issues (such as short or tall stature, dysthyroidism, abnormal pubertal timing or impaired glucose metabolism), which relevantly contribute to the global care of a number of syndromic conditions. On the other hand, the presence of endocrine features may assist in the diagnostic process, leading to final diagnosis of a syndromic disorder. The intention of this review is to provide a referenced overview of different genetic syndromes characterized by endocrine features, and to present a possible classification, based on whether the endocrinopathy or the syndrome is typically recognized first. Thus, the first part of the manuscript deals with the most common syndromes associated with endocrine dysfunctions, while the second part describes the conditions by which a syndrome is most frequently diagnosed after an endocrine finding. The aim is to provide a practical overview of the assessment of syndromic patients, so that they can be recognized and managed in an integrated, multidisciplinary fashion.


Assuntos
Doenças do Sistema Endócrino/genética , Transtornos do Crescimento/genética , Hormônio do Crescimento Humano/genética , Estatura/genética , Criança , Doenças do Sistema Endócrino/metabolismo , Doenças do Sistema Endócrino/patologia , Endocrinologistas , Transtornos do Crescimento/epidemiologia , Transtornos do Crescimento/patologia , Hormônio do Crescimento Humano/metabolismo , Humanos , Pediatria/tendências
6.
Ann Surg Oncol ; 27(2): 587-596, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31562603

RESUMO

BACKGROUND: Total pancreatectomy (TP) is rarely performed due to concerns for endocrine and exocrine insufficiency and decreased quality of life (QoL). Renewed interest is seen in recent years, but large cohort studies remain scarce. This study was designed to evaluate endocrine and exocrine insufficiency after TP and its impact on QoL. METHODS: Adult patients (age ≥ 18 years) who underwent TP between 2008 and 2017 at Karolinska University Hospital with at least 6 months follow-up were included. Endocrine and exocrine insufficiency and QoL were assessed using validated questionnaires (EORTC QLQ-C30, QLQ-PAN26, PAID20, and DTSQs). Both pre- and postoperative questionnaires were available in a subgroup. RESULTS: Of 145 TP, 60 patients were eligible of whom 53 (88.3%) with a median of 21 months (interquartile range [IQR] 13-54) follow-up were included. Symptomatic hypoglycemia occurred in 90.6% (48/53) of patients, and 25% (12/48) experienced ≥ 1 episodes of loss of consciousness. The PAID20 revealed emotional burnout in seven patients (13.2%), whereas a high satisfaction score of diabetes treatment (median 28, IQR 24-32) was measured according to the DTSQs. Overall, 27 patients (50.9%) reported to have steatorrhea during a median of 2 days (IQR 0-4) in the past week. Overall QoL was reduced compared with a general population (66.7% vs. 76.4%; Δ9.7%) but did not differ with preoperative outcomes (n = 39, 66.7%; IQR 41.7-83.3 vs. 66.7%, IQR 50.0-83.3; P = 0.553) according to the EORTC QLQ-C30. CONCLUSIONS: Although the impact of endocrine and exocrine insufficiency on QoL after TP seems acceptable, the management of both insufficiencies should be further improved.


Assuntos
Diabetes Mellitus/cirurgia , Doenças do Sistema Endócrino/psicologia , Insuficiência Pancreática Exócrina/psicologia , Ilhotas Pancreáticas/patologia , Pancreatectomia/efeitos adversos , Neoplasias Pancreáticas/cirurgia , Qualidade de Vida , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Diabetes Mellitus/patologia , Doenças do Sistema Endócrino/etiologia , Doenças do Sistema Endócrino/patologia , Insuficiência Pancreática Exócrina/etiologia , Insuficiência Pancreática Exócrina/patologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/patologia , Prognóstico , Inquéritos e Questionários , Adulto Jovem
7.
J Clin Endocrinol Metab ; 105(3)2020 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-31511863

RESUMO

CONTEXT: The increased use of opioids has resulted in an unprecedented opioid epidemic. Chronic opioid use causes hypogonadism, but its frequency, as well as the effects of opioids on other hypothalamo-pituitary-end organ hormone axes, remains unclear. OBJECTIVE: The aim of this systematic review and meta-analysis was to assess the effects of opioid use on pituitary function. METHODS: Eight electronic databases were searched for articles published up to May 8, 2018. Fixed or random effects meta-analysis was performed to estimate pooled proportions with 95% confidence intervals (CI). This study is reported following the PRISMA and MOOSE guidelines. DATA SYNTHESIS: 52 studies (22 low risk of bias) were included describing 18 428 subjects, consisting of patients with chronic pain (n = 21 studies) or on maintenance treatment for opioid addiction (n = 9) and healthy volunteers (n = 4). The most frequently used opioid was methadone (n = 13 studies), followed by morphine (n = 12). Prevalence of hypogonadism was 63% (95% CI: 55%-70%, 15 studies, 3250 patients, 99.5% males). Prevalence of hypocortisolism relying on dynamic and nondynamic testing was 15% (95% CI: 6%-28%, 5 studies, 205 patients, 57.5% males) and including only studies using the insulin tolerance tests 24% (95% CI 16%-33%, 2 studies, n = 97 patients). In 5 out of 7 studies, hyperprolactinemia was present. No clear effects on the somatotropic and hypothalamo-pituitary-thyroid axes were described. CONCLUSIONS: Hypogonadism occurs in more than half of male opioid users, and hypocortisolism in approximately one-fifth of all patients. Periodical evaluation of at least the gonadal and adrenal axes is therefore advisable.


Assuntos
Analgésicos Opioides/efeitos adversos , Dor Crônica/tratamento farmacológico , Doenças do Sistema Endócrino/patologia , Hipogonadismo/patologia , Dor Crônica/patologia , Doenças do Sistema Endócrino/induzido quimicamente , Humanos , Hipogonadismo/induzido quimicamente , Hormônios Hipofisários/metabolismo , Prognóstico
8.
Turk J Haematol ; 37(2): 111-115, 2020 05 06.
Artigo em Inglês | MEDLINE | ID: mdl-31876135

RESUMO

Chemotherapy treatment and autologous and allogeneic cell transplantations are often complicated by the onset of metabolic and endocrine disorders. Autoimmune disorders, metabolic diseases, and hormonal dysfunctions are some of the endocrine complications observed during or after treatment with immunotherapy (mostly novel agents) and/or chemotherapy conditioning for transplantation. Although successful treatment of the underlying hematological condition often improves the dysfunction, endocrinopathies can have an impact on prognosis and are associated with poor survival; therefore, it is important to detect and treat them as early as possible. An increased incidence of cardiovascular diseases and metabolic syndrome has been observed after transplantation mostly in long-term survivors. In addition, chemotherapy and radiation along with the prolonged use of corticosteroids can contribute to the onset of thyroid and gonadal dysfunctions. The aim of this article is to describe metabolic dysfunctions occurring in patients who underwent allogeneic cell transplantation.


Assuntos
Doenças do Sistema Endócrino/etiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Doenças Metabólicas/etiologia , Doenças do Sistema Endócrino/patologia , Humanos , Doenças Metabólicas/patologia
9.
Orphanet J Rare Dis ; 14(1): 275, 2019 12 02.
Artigo em Inglês | MEDLINE | ID: mdl-31791361

RESUMO

BACKGROUND: Gaucher disease (GD) is one of the most prevalent lysosomal storage diseases and is associated with hormonal and metabolic abnormalities, including nutritional status disorders, hypermetabolic state with high resting energy expenditures, peripheral insulin resistance, hypoadiponectinaemia, leptin and ghrelin impairments, hypolipidaemia, linear growth deceleration and growth hormone deficiency, delayed puberty, hypocalcaemia and vitamin D deficiency. Specific treatments for GD such as enzyme replacement therapy and substrate reduction therapy display significant effects on the metabolic profile of GD patients. Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1. GD1 appears to facilitate the development of disorders of nutrition, glucose metabolism and vitamin D insufficiency. Metabolic and hormonal diseases may have a significant impact on the course of the underlying disease and patient quality of life. CONCLUSIONS: Conditions relating to hormones and metabolism can be wide-ranging in GD1. Obtained findings were intrinsic to GD either as a deleterious process or a compensatory response and some changes detected may represent co-morbidities. Actively seeking and diagnosing endocrine and metabolic disorders are strongly recommended in GD1 patients to optimize healthcare.


Assuntos
Doenças do Sistema Endócrino/epidemiologia , Doenças do Sistema Endócrino/patologia , Doença de Gaucher/epidemiologia , Doença de Gaucher/patologia , Doenças Metabólicas/epidemiologia , Doenças Metabólicas/patologia , Humanos , Obesidade/epidemiologia , Obesidade/patologia , Qualidade de Vida , Deficiência de Vitamina D/epidemiologia , Deficiência de Vitamina D/patologia
10.
Future Med Chem ; 11(16): 2171-2192, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31538528

RESUMO

This review article aims to synthesize the evidence regarding nonalcoholic fatty liver disease (NAFLD) as a systemic disorder. We critically discuss the metabolic syndrome and its components; the cardiovascular and the endocrine system; chronic respiratory disorders; the musculoskeletal system; the skin; and extra-hepatic tumors. We conclude that, while some of these extra-hepatic conditions clearly predispose to the development of secondary forms of NAFLD (typically hypothyroidism-induced NAFLD), others result from pre-existent NAFLD (e.g., certain extra-hepatic tumors) and others (such as Type 2 Diabetes) have, with NAFLD, mutual and bidirectional associations. Analyzed data imply that NAFLD is not merely a hepatic disease. It is also and possibly more importantly, a systemic disorder requiring a special awareness, a multidisciplinary approach and a multidimensional vision.


Assuntos
Hepatopatia Gordurosa não Alcoólica/complicações , Animais , Doenças Ósseas/etiologia , Doenças Ósseas/patologia , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/patologia , Doenças do Sistema Endócrino/etiologia , Doenças do Sistema Endócrino/patologia , Humanos , Doenças Metabólicas/etiologia , Doenças Metabólicas/patologia , Doenças Musculares/etiologia , Doenças Musculares/patologia , Neoplasias/etiologia , Neoplasias/patologia , Hepatopatia Gordurosa não Alcoólica/patologia , Insuficiência Renal Crônica/etiologia , Insuficiência Renal Crônica/patologia
11.
Life Sci ; 233: 116689, 2019 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-31348949

RESUMO

BACKGROUND: Maternal metabolic syndrome during gestation and lactation leads to several Se-status-related metabolic changes in offspring. MS leads to hepatomegaly, liver oxidation, resistance to insulin challenges and selenoptroteins expression upregulation, producing an energy imbalance in hepatocytes. As Se is necessary for correct heart function, Se deposits are depleted and selenoproteins expression downregulated in heart; this depletion being related to cardiovascular damage. Recently, selenoproteins have been directly implicated in the central endocrine regulation of appetite and energy homeostasis. METHODS: To obtain information about how Se is involved in regulating endocrine peripheral energy balance during MS process, two experimental groups of dam rats were used: control (Se: 0.1 ppm) and MS (Fructose 65% and Se: 0.1 ppm). At the end of lactation (21d old), the pups' appetite profile, tissular Se deposits and peptides from gastrointestinal tract (including pancreas), leptin, skeletal growth markers and cytokines in serum were measured. RESULTS: MS-exposed pups present changes in Se homeostasis, appetite profile and endocrine energy balance signals related to impaired insulin secretion and high leptin serum values. This profoundly affects the pups' growth profile since muscle and bones are in catabolic process and brown adipose tissue (BAT) mass decreases. CONCLUSION: These results indicate that the pups are suffering a process similar to diabetes type 1 which appeared when dams received low Se dietary supply and they point to Se as an important marker and key treatment for these disorders during gestation and lactation that affect future adult health.


Assuntos
Doenças do Sistema Endócrino/etiologia , Metabolismo Energético/efeitos dos fármacos , Desenvolvimento Fetal/efeitos dos fármacos , Síndrome Metabólica/complicações , Efeitos Tardios da Exposição Pré-Natal/fisiopatologia , Selênio/administração & dosagem , Animais , Biomarcadores/sangue , Doenças do Sistema Endócrino/patologia , Feminino , Homeostase , Resistência à Insulina , Leptina/sangue , Masculino , Fenômenos Fisiológicos da Nutrição Materna , Síndrome Metabólica/tratamento farmacológico , Estresse Oxidativo , Gravidez , Efeitos Tardios da Exposição Pré-Natal/etiologia , Ratos , Ratos Wistar , Selênio/efeitos adversos , Selênio/sangue
12.
Am J Physiol Endocrinol Metab ; 317(5): E731-E741, 2019 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-31287713

RESUMO

We previously demonstrated that androgen signaling expands pancreatic ß-cell mass in the sexual maturation period (Am J Physiol Endocrinol Metab 314: E274-E286, 2018). The aim of this study was to elucidate whether fetal androgen signaling plays important roles in ß-cell mass development and ß-cell function in adulthood, defects of which are associated with type 2 diabetes mellitus. In the pancreas of male fetuses, androgen receptor (AR) was strongly expressed in the cytoplasm and at the cell membrane of Nkx6.1-positive ß-cell precursor cells but was markedly reduced in insulin-positive ß-cells. Administration of the anti-androgen flutamide to pregnant dams during late gestation reduced ß-cell mass and Ki67-positive proliferating ß-cells at birth in a male-specific manner without affecting body weight. The decrease of ß-cell mass in flutamide-exposed male rats was not recovered when rats were fed a standard diet, whereas it was fully recovered when rats were fed a high-fat diet (HFD), at 6 and 12 wk of age. Flutamide exposure in utero led to the development of glucose intolerance in male rats due to a decrease in insulin secretion when fed HFD but not standard diet. Insulin sensitivity did not differ between the two groups irrespective of diet. These results indicated that the action of fetal androgen contributed to ß-cell mass expansion in a sex-specific manner at birth and to the development of glucose intolerance by decreasing the secretion of insulin in HFD-fed male rats. Our data demonstrated the involvement of fetal androgen signaling in hypothesized sex differences in the developmental origins of health and disease by affecting pancreatic ß-cell function.


Assuntos
Androgênios/metabolismo , Dieta Hiperlipídica , Doenças do Sistema Endócrino/patologia , Feto/fisiopatologia , Intolerância à Glucose/metabolismo , Células Secretoras de Insulina/patologia , Antagonistas de Androgênios/farmacologia , Animais , Composição Corporal , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patologia , Doenças do Sistema Endócrino/metabolismo , Doenças do Sistema Endócrino/fisiopatologia , Feminino , Flutamida/farmacologia , Intolerância à Glucose/etiologia , Secreção de Insulina/efeitos dos fármacos , Metabolismo dos Lipídeos , Masculino , Gravidez , Ratos , Ratos Wistar , Receptores Androgênicos/biossíntese , Receptores Androgênicos/genética , Caracteres Sexuais , Transdução de Sinais
13.
Dis Markers ; 2019: 4360612, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31191750

RESUMO

A growing interest in the usability of saliva has been observed recently. Using saliva as a diagnostic material is possible because it contains a varied range of composites, organic and inorganic like proteins, carbohydrates, and lipids, which are secreted into saliva. Moreover, this applies to drugs and their metabolites. Saliva collection is noninvasive, and self-collection is possible. There is a lack of risk of injuries related to injection with needle, and it is generally safe. Human saliva has been successfully used, for example, in the diagnosis of many systemic diseases like cancers, autoimmunological diseases, infectious diseases (HIV, hepatitis, and malaria), and endocrinological diseases, as well as diseases of the gastrointestinal tract. Also, it is used in toxicological diagnostics, drug monitoring, and forensic medicine. The usefulness of saliva as a biological marker has also been extended to psychiatry. The specificity of mental illness and patients limits or prevents cooperation and diagnosis. In many cases, the use of saliva as a marker seems to be the most sensible choice.


Assuntos
Alcoolismo/metabolismo , Transtorno do Espectro Autista/metabolismo , Biomarcadores/metabolismo , Doenças do Sistema Endócrino/metabolismo , Saliva/metabolismo , Alcoolismo/patologia , Transtorno do Espectro Autista/patologia , Biomarcadores/análise , Demência , Monitoramento de Medicamentos/métodos , Doenças do Sistema Endócrino/patologia , Humanos , Saliva/química
14.
Eur J Endocrinol ; 181(2): R73-R105, 2019 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-31242462

RESUMO

In the currently overwhelming era of polypharmacy, the balance of the dynamic and delicate endocrine system can easily be disturbed by interfering pharmaceutical agents like medications. Drugs can cause endocrine abnormalities via different mechanisms, including direct alteration of hormone production, changes in the regulation of the feedback axis, on hormonal transport, binding and signaling, as well as similar changes to counter-regulatory hormone systems. Furthermore, drugs can interfere with the hormonal assays, leading to erroneous laboratory results that disorientate clinicians from the right diagnosis. The purpose of this review is to cover a contemporary topic, the drug-induced endocrinopathies, which was presented in the monothematic annual Combo Endo Course 2018. This challenging part of endocrinology is constantly expanding particularly during the last decade, with the new oncological therapeutic agents, targeting novel molecular pathways in the process of malignancies. In this new context of drug-induced endocrine disease, clinicians should be aware that drugs can cause endocrine abnormalities via different mechanisms and mimic a variety of clinical scenarios. Therefore, it is extremely important for clinicians not only to promptly recognize drug-induced hormonal and metabolic abnormalities, but also to address the therapeutic issues for timely intervention.


Assuntos
Diabetes Mellitus/metabolismo , Doenças do Sistema Endócrino/induzido quimicamente , Doenças do Sistema Endócrino/patologia , Sistema Endócrino/patologia , Endocrinologia/métodos , Animais , Diabetes Mellitus/diagnóstico , Sistema Endócrino/efeitos dos fármacos , Humanos
15.
Int J Mol Sci ; 20(11)2019 Jun 11.
Artigo em Inglês | MEDLINE | ID: mdl-31212642

RESUMO

Secondary nonalcoholic fatty liver disease (NAFLD) defines those complex pathophysiological and clinical consequences that ensue when the liver becomes an ectopic site of lipid storage owing to reasons other than its mutual association with the metabolic syndrome. Disorders affecting gonadal hormones, thyroid hormones, or growth hormones (GH) may cause secondary forms of NAFLD, which exhibit specific pathophysiologic features and, in theory, the possibility to receive an effective treatment. Here, we critically discuss epidemiological and pathophysiological features, as well as principles of diagnosis and management of some common endocrine diseases, such as polycystic ovary syndrome (PCOS), hypothyroidism, hypogonadism, and GH deficiency. Collectively, these forms of NAFLD secondary to specific endocrine derangements may be envisaged as a naturally occurring disease model of NAFLD in humans. Improved understanding of such endocrine secondary forms of NAFLD promises to disclose novel clinical associations and innovative therapeutic approaches, which may potentially be applied also to selected cases of primary NAFLD.


Assuntos
Doenças do Sistema Endócrino/epidemiologia , Doenças do Sistema Endócrino/patologia , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Animais , Doenças do Sistema Endócrino/metabolismo , Feminino , Humanos , Hipogonadismo/epidemiologia , Hipogonadismo/metabolismo , Hipogonadismo/patologia , Hipotireoidismo/epidemiologia , Hipotireoidismo/metabolismo , Hipotireoidismo/patologia , Masculino , Hepatopatia Gordurosa não Alcoólica/metabolismo , Hepatopatia Gordurosa não Alcoólica/patologia , Síndrome do Ovário Policístico/epidemiologia , Síndrome do Ovário Policístico/metabolismo , Síndrome do Ovário Policístico/patologia
16.
Nat Rev Endocrinol ; 15(8): 444-455, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31127254

RESUMO

The blood-brain barrier (BBB) was first noted for its ability to prevent the unregulated exchange of substances between the blood and the central nervous system (CNS). Over time, its characterization as an interface that enables regulated exchanges between the CNS and substances that are carried in the blood in a hormone-like fashion have emerged. Therefore, communication between the CNS, BBB and peripheral tissues has many endocrine-like properties. In this Review, I examine the various ways in which the BBB exhibits endocrine-related properties. The BBB is a target for hormones, such as leptin and insulin, that affect many of its functions. The BBB is also a secretory body, releasing substances either into the blood or the interstitial fluid of the brain. The BBB selectively allows classical and non-classical hormones entry to and exit from the CNS, thus allowing the CNS to be both an endocrine target and a secretory tissue. The BBB is affected by endocrine diseases such as diabetes mellitus and can cause or participate in endocrine diseases, including those related to thyroid hormones and obesity. The endocrine-like mechanisms of the BBB can extend the definition of endocrine disease to include neurodegenerative conditions, including Alzheimer disease, and of hormones to include cytokines, triglycerides and fatty acids.


Assuntos
Barreira Hematoencefálica/metabolismo , Doenças do Sistema Endócrino/metabolismo , Endocitose/fisiologia , Hormônios/metabolismo , Animais , Sistema Endócrino/metabolismo , Doenças do Sistema Endócrino/patologia , Humanos
17.
Biomed Res Int ; 2019: 6573497, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31119181

RESUMO

Background: Endocrinopathies are common in patients with ß-thalassemia major despite parenteral iron chelation therapy with deferoxamine. Prevalence of abnormal glucose metabolism in previous studies was controversial. The aim of this study was to discuss the prevalence of abnormal glucose metabolism in ß-thalassemia major based on a meta-analysis. Methods: PubMed, ScienceDirect, Springerlink, Ovid, Web of Science, MEDLINE, Wanfang database, and Chinese National Knowledge Internet were searched for relevant articles. Two authors selected the articles according to the inclusion criteria and then extracted the data. The prevalence of diabetes mellitus (DM) in ß-thalassemia major was defined as the primary outcome. The prevalence with the 95% confidence interval (95%CI) was used to evaluate the proportion of abnormal glucose metabolism and other endocrine disorders in patients with ß-thalassemia major. Subgroup analyses were applied to explore the prevalence in different regions. Sensitivity analysis and publication bias assessment were also conducted. Results: A total of 44 studies with 16605 cases were included in this analysis. Diabetes mellitus was present in 6.54% (95% CI: 5.30%-7.78%). The fixed subgroup study revealed that the region with the highest prevalence was the Middle East (prevalence= 7.90%, 95% CI: 5.75%-10.05%). The accumulated meta-analysis revealed that the prevalence of DM in ß-thalassemia major was relatively steady in each year. The prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and other endocrine disorders in ß-thalassemia major was 17.21% (95% CI: 8.43%-26.00%), 12.46% (95% CI: 5.98%-18.94%), and 43.92% (95% CI: 37.94%-49.89%), respectively. Sensitivity analysis showed that the pooled results were robust; publication bias assessment revealed that there was no significant evidence that the pooled results were influenced by publication bias. Conclusion: High prevalence of endocrine disorders involving abnormal glucose metabolism was detected in ß-thalassemia major. Treatment and prevention measurements may be necessary to prevent growth and endocrine problems.


Assuntos
Diabetes Mellitus/epidemiologia , Doenças do Sistema Endócrino/epidemiologia , Glucose/metabolismo , Talassemia beta/epidemiologia , Terapia por Quelação , Desferroxamina/uso terapêutico , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patologia , Doenças do Sistema Endócrino/complicações , Doenças do Sistema Endócrino/metabolismo , Doenças do Sistema Endócrino/patologia , Intolerância à Glucose , Humanos , Quelantes de Ferro/uso terapêutico , Oriente Médio/epidemiologia , Talassemia beta/complicações , Talassemia beta/metabolismo , Talassemia beta/patologia
18.
J Allergy Clin Immunol ; 144(2): 375-380, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31004615

RESUMO

Pruritus is a sensation that emanates from the skin and is transferred through peripheral nerve fibers to the central nervous system. It is easily understood that primary skin disorders, such as atopic eczema, skin dryness, psoriasis, and urticaria, can elicit pruritus. However, certain systemic diseases can cause chronic pruritus, which has a significant effect on the patient's quality of life. In this rostrum we provide an overview of the characteristics, pathophysiology, and mechanisms of pruritus of major systemic underlying diseases, including end-stage renal disease, cholestatic liver disease, endocrine/metabolic diseases, and hematologic/lymphoproliferative diseases.


Assuntos
Doenças do Sistema Endócrino/imunologia , Falência Renal Crônica/imunologia , Transtornos Linfoproliferativos/imunologia , Doenças Metabólicas/imunologia , Prurido/imunologia , Qualidade de Vida , Pele/imunologia , Dermatite Atópica/imunologia , Dermatite Atópica/patologia , Doenças do Sistema Endócrino/patologia , Humanos , Falência Renal Crônica/patologia , Transtornos Linfoproliferativos/patologia , Doenças Metabólicas/patologia , Prurido/patologia , Psoríase/imunologia , Psoríase/patologia , Pele/patologia , Urticária/imunologia , Urticária/patologia
19.
Indian J Pediatr ; 86(10): 939-951, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-30887222

RESUMO

Short stature in children is a diagnostic challenge to the physician. Bone age assessment can be done using various methods. The causes of short stature are variable; often leading to a series of investigations. The endocrine conditions have typical imaging features. This chapter provides a short overview of the methods of bone age estimation, and imaging findings and algorithmic approach towards a child with short stature.


Assuntos
Determinação da Idade pelo Esqueleto/métodos , Diagnóstico por Imagem/métodos , Transtornos do Crescimento/diagnóstico por imagem , Algoritmos , Criança , Síndrome de Cushing/diagnóstico por imagem , Síndrome de Cushing/patologia , Doenças do Sistema Endócrino/diagnóstico por imagem , Doenças do Sistema Endócrino/patologia , Glioma/diagnóstico por imagem , Glioma/patologia , Transtornos do Crescimento/patologia , Hamartoma/diagnóstico por imagem , Hamartoma/patologia , Histiocitose de Células de Langerhans/diagnóstico por imagem , Histiocitose de Células de Langerhans/patologia , Humanos , Hipopituitarismo/diagnóstico por imagem , Hipopituitarismo/patologia , Doenças Hipotalâmicas/diagnóstico por imagem , Doenças Hipotalâmicas/patologia , Hipotireoidismo/diagnóstico por imagem , Hipotireoidismo/patologia , Doenças da Hipófise/diagnóstico por imagem , Doenças da Hipófise/patologia , Hipófise/diagnóstico por imagem , Hipófise/patologia , Hormônios Hipofisários , Puberdade Precoce/diagnóstico por imagem , Puberdade Precoce/patologia
20.
PLoS One ; 14(2): e0212360, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30779814

RESUMO

BACKGROUND: Trustworthy (i.e. low risk of bias) randomized clinical trials (RCTs) play an important role in evidence-based decision making. We aimed to systematically assess the risk of bias of trials published in high-impact endocrinology journals. METHODS: We searched the MEDLINE/PubMed database between 2014 and 2016 for phase 2-4 RCTs evaluating endocrine-related therapies. Reviewers working independently and in duplicate used the Cochrane Risk of Bias Tool (CCRBT) to determine the extent to which the methods reported protected the results of each RCT from bias. RESULTS: We assessed 292 eligible RCTs, of which 40% (116) were judged to be at low risk, 43% (126) at moderate, and 17% (50) at high risk of bias. Blinding of outcome assessment was the least common domain reported 43% (125), while selective reporting of outcomes was the most common 97% (282). In multivariable analysis, RCTs with a parallel design (OR 2.4; 95% CI; 1.2-4.6) and funded by for-profit sources (OR 2.2; 95% CI; 1.3-3.6) were more likely to be at low risk of bias. CONCLUSIONS: Trustworthy evidence should ultimately shape care to improve the likelihood of desirable patient outcomes. Six out-of 10 RCTs published in top endocrine journals are at moderate/high-risk of bias. Improving this should be a priority in endocrine research.


Assuntos
Doenças do Sistema Endócrino/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Doenças Ósseas/metabolismo , Doenças Ósseas/patologia , Doenças Ósseas/terapia , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/patologia , Doenças Cardiovasculares/terapia , Bases de Dados Factuais , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patologia , Diabetes Mellitus/terapia , Doenças do Sistema Endócrino/metabolismo , Doenças do Sistema Endócrino/patologia , Humanos , Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...